Merck & Company Inc (MRK)vsVericel Corp Ord (VCEL)
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
VCEL
Vericel Corp Ord
$38.34
+1.24%
HEALTHCARE · Cap: $2.06B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 21633% more annual revenue ($66.57B vs $306.30M). VCEL leads profitability with a 7.9% profit margin vs 4.8%. VCEL trades at a lower P/E of 83.7x. VCEL earns a higher WallStSmart Score of 42/100 (D).
MRK
Hold36
out of 100
Grade: F
VCEL
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Intrinsic value data unavailable for VCEL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 22.5% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Distress zone — elevated risk
ROE of 6.0% — below average capital efficiency
7.9% margin — thin
Operating margin of 0.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VCEL
The strongest argument for VCEL centers on Debt/Equity, Revenue Growth. Revenue growth of 22.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VCEL
The primary concerns for VCEL are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 83.7x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while VCEL is a growth play — different risk/reward profiles.
VCEL carries more volatility with a beta of 1.05 — expect wider price swings.
VCEL is growing revenue faster at 22.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
VCEL scores higher overall (42/100 vs 36/100) and 22.5% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vericel Corp Ord
HEALTHCARE · BIOTECHNOLOGY · USA
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?